Search Page

1

Cite

Share

The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD).

Mager DR, Iñiguez IR, Gilmour S, Yap J. Mager DR, et al. JPEN J Parenter Enteral Nutr. 2015 Jan;39(1):73-84. doi: 10.1177/0148607113501201. Epub 2013 Aug 23. JPEN J Parenter Enteral Nutr. 2015. PMID: 23976771

Cite

Share

2

Cite

Share

Common features of the metabolic syndrome and nonalcoholic fatty liver disease.

Almeda-Valdes P, Aguilar-Olivos N, Uribe M, Méndez-Sánchez N. Almeda-Valdes P, et al. Rev Recent Clin Trials. 2014;9(3):148-58. doi: 10.2174/1574887109666141216103908. Rev Recent Clin Trials. 2014. PMID: 25514910 Review.

Cite

Share

3

Cite

Share

The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients.

Luukkonen PK, Qadri S, Lehtimäki TE, Juuti A, Sammalkorpi H, Penttilä AK, Hakkarainen A, Orho-Melander M, Arola J, Yki-Järvinen H. Luukkonen PK, et al. J Clin Endocrinol Metab. 2021 Jan 1;106(1):e300-e315. doi: 10.1210/clinem/dgaa729. J Clin Endocrinol Metab. 2021. PMID: 33064150

Cite

Share

4

Cite

Share

Honokiol Alleviates Methionine-Choline Deficient Diet-Induced Hepatic Steatosis and Oxidative Stress in C57BL/6 Mice by Regulating CFLAR-JNK Pathway.

Zhai T, Xu W, Liu Y, Qian K, Xiong Y, Chen Y. Zhai T, et al. Oxid Med Cell Longev. 2020 Nov 27;2020:2313641. doi: 10.1155/2020/2313641. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 33354276 Free PMC article.

Cite

Share

5

Cite

Share

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship.

Muzica CM, Sfarti C, Trifan A, Zenovia S, Cuciureanu T, Nastasa R, Huiban L, Cojocariu C, Singeap AM, Girleanu I, Chiriac S, Stanciu C. Muzica CM, et al. Can J Gastroenterol Hepatol. 2020 Dec 28;2020:6638306. doi: 10.1155/2020/6638306. eCollection 2020. Can J Gastroenterol Hepatol. 2020. PMID: 33425804 Free PMC article. Review.

Cite

Share

6

Cite

Share

2,3,5,4'-tetrahydroxy-stilbene-2-O-β-D-glucoside ameliorates NAFLD via attenuating hepatic steatosis through inhibiting mitochondrial dysfunction dependent on SIRT5.

Zhang S, Wu Z, Shi L, Yan S, Huang Z, Lu B, Wang Z, Ji L. Zhang S, et al. Phytomedicine. 2022 Feb 14;99:153994. doi: 10.1016/j.phymed.2022.153994. Online ahead of print. Phytomedicine. 2022. PMID: 35220131

Cite

Share

7

Cite

Share

Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo.

Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Williams KH, et al. Endocr Rev. 2013 Feb;34(1):84-129. doi: 10.1210/er.2012-1009. Epub 2012 Dec 13. Endocr Rev. 2013. PMID: 23238855 Review.

Cite

Share

8

Cite

Share

Fetuin-A as a Potential Biomarker of Metabolic Variability Following 60 Days of Bed Rest.

Ward K, Mulder E, Frings-Meuthen P, O'Gorman DJ, Cooper D. Ward K, et al. Front Physiol. 2020 Oct 19;11:573581. doi: 10.3389/fphys.2020.573581. eCollection 2020. Front Physiol. 2020. PMID: 33192574 Free PMC article.

Cite

Share

9

Cite

Share

Pathophysiology of NASH: perspectives for a targeted treatment.

Marra F, Lotersztajn S. Marra F, et al. Curr Pharm Des. 2013;19(29):5250-69. doi: 10.2174/13816128113199990344. Curr Pharm Des. 2013. PMID: 23394092 Free PMC article.

Cite

Share

10

Cite

Share

Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].

Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, Byrne CD; WELCOME Trial Investigators. Scorletti E, et al. Contemp Clin Trials. 2014 Mar;37(2):301-11. doi: 10.1016/j.cct.2014.02.002. Epub 2014 Feb 18. Contemp Clin Trials. 2014. PMID: 24556343 Clinical Trial.

Cite

Share